Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Antiviral Res ; 200: 105289, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35301060

RESUMO

For human immunodeficiency virus 1 (HIV-1) to infect non-dividing cells, pre-integration complex (PIC) must be transported into the nucleus within the replication cycle. We previously reported that the karyopherin ß1 (KPNB1)-nucleoporin Pom121 pathway, related to the downstream process of PIC nuclear import, mediates efficient HIV-1 PIC nuclear import. Further, our earlier RNA transcriptome sequencing revealed that karyopherin α2 (KPNA2) was among the differentially expressed importin family members during monocyte to macrophage differentiation. Although PIC transport into the nucleus in HIV-1 has been widely studied, much remains to be understood about it. In this study, we confirmed our previous RNA sequencing results and found that HIV-1 replication was significantly lower in 293T cells with siRNA-mediated KPNA2 knockdown and higher in KPNA2-upregulated cells. Quantitative PCR indicated that viral replication was impaired during cDNA nuclear import. The N-terminal of the capsid protein p24 interacted with KPNA2, and KPNB1 participated in KPNA2-mediated PIC nuclear import. Disruption of the capsid-KPNA2 binding by overexpression of full-length p24 or p24 N-terminal impaired the PIC nuclear import. These results indicate that KPNA2 is an important upstream adaptor of the KPNB1-Pom121 axis, thereby mediating HIV-1 PIC nuclear transportation. KPNA2 is thus a potential target for HIV-1 antiviral treatment.


Assuntos
HIV-1 , Transporte Ativo do Núcleo Celular , Proteínas do Capsídeo/genética , Proteínas do Capsídeo/metabolismo , Núcleo Celular/metabolismo , HIV-1/genética , HIV-1/metabolismo , Humanos , Carioferinas/metabolismo , Glicoproteínas de Membrana/metabolismo , Replicação Viral , alfa Carioferinas/genética , alfa Carioferinas/metabolismo
2.
Yi Chuan ; 37(10): 974-82, 2015 10.
Artigo em Inglês | MEDLINE | ID: mdl-26496749

RESUMO

CRISPR/Cas system is an adaptive immune system that confers resistance to exogenous virus or plasmid in bacteria and archaea. In recent years, the booming CRISPR/Cas9 genome editing technology modified from type2 CRISPR/Cas adaptive immune system has been widely applied to various research fields of life science and led to revolutionary changes. In this review, we summarize the origin and development of CRISPR/Cas9 genome editing technology as well as its applications in life science research. We focus on the latest application of this system in gene therapy of human diseases and the associated side/off-target effects, which may provide references for researchers in related areas.


Assuntos
Imunidade Adaptativa/genética , Sistemas CRISPR-Cas , Engenharia Genética/métodos , Terapia Genética/métodos , Endonucleases/genética , Endonucleases/metabolismo , Engenharia Genética/tendências , Terapia Genética/tendências , Infecções por HIV/genética , Infecções por HIV/imunologia , Infecções por HIV/terapia , Humanos , Modelos Genéticos , Neoplasias/genética , Neoplasias/imunologia , Neoplasias/terapia , RNA Guia de Cinetoplastídeos/genética , RNA Guia de Cinetoplastídeos/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...